跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CAMZYOS - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
CAMZYOS
Authorized
STANDARD
CAMZYOS
bristol-myers squibb canada
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
1276fdb8305d7aac
Company
bristol-myers squibb canada
Type
Standard
Approval Details
Approval Id
1276fdb8305d7aac
Drug Approval Canada Name
CAMZYOS
Product Name
CAMZYOS
Status
Marketed
Status Date
2023-08-08
Original Market Date
2023-08-08
Din
02532573
Drug Class
Human
Dosage Form
Capsule
Route Of Administration
Oral
Schedule
Prescription
Ahfs
24:04.92
Atc Original
C01EB24 MAVACAMTEN
Atc Name
c 01 eb 24
Aig Number
0164242004
Company Name
bristol-myers squibb canada
Company Address
2344 Boul. Alfred-Nobel, Suite 300, St-Laurent, Quebec, Canada, H4S 0A4
Active Ingredients
MAVACAMTEN
15 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
1276fdb8305d7aac
Type
Standard
Back to Health Canada Approvals